Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Elekta AB ( ($SE:EKTA.B) ) has issued an announcement.
Elekta announced that its MRI-guided adaptive radiation therapy platform, Elekta Unity, has shown to improve the quality of life for men with localized prostate cancer by reducing urinary symptoms. The study, presented at the 2025 ASTRO Annual Meeting, involved 630 patients and demonstrated that adapting radiation therapy to daily anatomical changes can lead to better long-term outcomes. This advancement highlights Elekta’s commitment to enhancing cancer treatment and preserving patients’ quality of life.
The most recent analyst rating on ($SE:EKTA.B) stock is a Hold with a SEK50.00 price target. To see the full list of analyst forecasts on Elekta AB stock, see the SE:EKTA.B Stock Forecast page.
More about Elekta AB
Elekta is a leader in precision radiation therapy, dedicated to providing access to advanced cancer care. With a focus on sustainable and outcome-driven solutions, Elekta collaborates with customers to improve patient lives and bring hope to those affected by cancer. Headquartered in Stockholm, Sweden, Elekta operates in over 40 countries and is listed on Nasdaq Stockholm.
YTD Price Performance: -19.74%
Average Trading Volume: 1,006,176
Technical Sentiment Signal: Sell
Current Market Cap: SEK17.88B
For detailed information about EKTA.B stock, go to TipRanks’ Stock Analysis page.